Literature DB >> 26981711

Comparative outcomes of active and passive hearing devices by transcutaneous bone conduction.

Mario Emilio Zernotti1, Maria Fernanda Di Gregorio1, Pablo Galeazzi1, Paola Tabernero2.   

Abstract

Conclusion Bonebridge (BB) and Sophono (SP) devices improved hearing; with the BB implant showing a better performance at medium and high frequencies. Furthermore, the BB, as an active implant, showed higher functional gain and increased time of use, when compared to the SP, a passive system. Objectives This study aims to compare surgical and audiological outcomes of SP and BB devices in order to assess and further differentiate the indication criteria. Methods Fourteen patients with conductive and mixed hearing loss were evaluated pre- and post-operatively (BB or SP) (period 2013-2014). Age, gender, surgical history, cause and type of hearing loss, implant use per day, levels of bone and air conduction, and functional gain were recorded. Data was analysed by Wilcoxon singed-rank and Wilcoxon rank-sum tests. Results Fourteen patients (BB; n = 10 and SP; n = 4) with an average age = 25.42 years (CI95 = 12.41-38.43) were evaluated. The gender relation was equal (1:1), with pre-implantation osseous thresholds of 20.42 dB (CI95 = 11.15-29.69), and pre-implantation aerial thresholds of 70.83 dB (CI95 = 62.52-79.14). The SP wearing time was significantly lower than that of the BB (SP = 7-10 h/day, BB = 8-12 h/day; p = 0.0323). The functional gain did not differ significantly between the two devices (BB = 40.00 ± 13.19 dB, SP = 34.06 ± 15.63 dB; p = 0.3434), but a significant improvement from pre- to post-implantation was observed (p < 0.05). BB and SP decreased auditory thresholds at 1 and 2 kHz (< 0.01), respectively. The BB even significantly decreased thresholds at 0.5 kHz (p = 0.0140) and 4 kHz (p < 0.0001). No relevant surgical complications were found.

Entities:  

Keywords:  Bone conduction hearing aids; Bonebridge; Sophono; conductive hearing loss

Mesh:

Year:  2016        PMID: 26981711     DOI: 10.3109/00016489.2016.1143119

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  7 in total

1.  Bone Conduction Implants for Hearing Rehabilitation in Skull Base Tumor Patients.

Authors:  Lauren Placke; Eric N Appelbaum; Akash J Patel; Alex D Sweeney
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-06

2.  Complications of Transcutaneous Protheses - A Systematic Review of Publications Over the Past 10 Years.

Authors:  Marcos Antonio de Souza; Santiago Luis Vallejos Riart; Stephanie Rugeri de Souza; Rubens de Brito; Ricardo Ferreira Bento
Journal:  Int Arch Otorhinolaryngol       Date:  2022-02-04

3.  Percutaneous Bone-Anchored Hearing Implant: Is It Clinically Useful in Korean?

Authors:  Sung Min Koh; Young Sang Cho; Ga-Young Kim; Mini Jo; Hye Yoon Seol; Il Joon Moon
Journal:  J Korean Med Sci       Date:  2022-06-13       Impact factor: 5.354

4.  Patient-reported long-term benefit with an active transcutaneous bone-conduction device.

Authors:  Julia Hundertpfund; Jens Eduard Meyer; Attila Óvári
Journal:  PLoS One       Date:  2020-11-02       Impact factor: 3.240

5.  Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes.

Authors:  Katarzyna B Cywka; Piotr H Skarzynski; Bartlomiej Krol; Stavros Hatzopoulos; Henryk Skarzynski
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-19       Impact factor: 3.236

6.  Active transcutaneous bone conduction hearing implants: Systematic review and meta-analysis.

Authors:  Astrid Magele; Philipp Schoerg; Barbara Stanek; Bernhard Gradl; Georg Mathias Sprinzl
Journal:  PLoS One       Date:  2019-09-16       Impact factor: 3.240

7.  Clinical and functional results after implantation of the bonebridge, a semi-implantable, active transcutaneous bone conduction device, in children and adults.

Authors:  Ingmar Seiwerth; Laura Fröhlich; Sebastian Schilde; Gerrit Götze; Stefan K Plontke; Torsten Rahne
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-06       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.